- Home
- ZLAB
ZLAB
Zai Lab Limited
as 08-29-2025 3:35pm EST
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
| Founded: | 2013 | Country: | China |
| Employees: | N/A | City: | SHANGHAI |
| Market Cap: | 4.0B | IPO Year: | 2017 |
| Target Price: | $57.22 | AVG Volume (30 days): | 538.8K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.03 | EPS Growth: | N/A |
| 52 Week Low/High: | $18.60 - $44.34 | Next Earning Date: | 08-07-2025 |
| Revenue: | $427,799,000 | Revenue Growth: | 32.56% |
| Revenue Growth (this year): | 42.62% | Revenue Growth (next year): | 55.12% |
Stock Insider Trading Activity of Zai Lab Limited (ZLAB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Smiley Joshua L | ZLAB | See Remarks | Aug 18 '25 | Sell | $36.24 | 6,641 | $240,643.28 | 76,604 | |
| Edmondson Frazor Titus III | ZLAB | Chief Legal Officer | Aug 18 '25 | Sell | $36.24 | 1,883 | $68,232.39 | 42,065 | |
| Chen Yajing | ZLAB | Chief Financial Officer | Aug 15 '25 | Sell | $35.40 | 1,438 | $50,931.71 | 17,548 | |
| Du Ying | ZLAB | Chairperson & CEO | Aug 13 '25 | Sell | $35.47 | 46,387 | $1,645,286.59 | 536,962 | |
| Du Ying | ZLAB | Chairperson & CEO | Aug 12 '25 | Sell | $34.25 | 50,000 | $1,712,555.00 | 536,962 | |
| Du Ying | ZLAB | Chairperson & CEO | Aug 11 '25 | Sell | $34.64 | 50,000 | $1,731,815.00 | 536,962 | |
| Du Ying | ZLAB | Chairperson & CEO | Aug 8 '25 | Sell | $34.74 | 50,000 | $1,737,155.00 | 536,962 | |
| Chen Yajing | ZLAB | Chief Financial Officer | Aug 8 '25 | Sell | $34.01 | 4,096 | $139,304.96 | 17,548 | |
| Amado Rafael | ZLAB | See Remarks | Aug 8 '25 | Sell | $35.00 | 3,000 | $105,000.00 | 42,178 | |
| Chen Yajing | ZLAB | Chief Financial Officer | Jun 2 '25 | Sell | $30.00 | 9,618 | $288,540.00 | 17,548 |
Latest Zai Lab Limited News
ZLAB Breaking Stock News: Dive into ZLAB Ticker-Specific Updates for Smart Investing
Business Wire
2 months ago
Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer
Argus Research
2 months ago
Daily – Vickers Top Buyers & Sellers for 06/30/2025
MT Newswires
2 months ago
Asian Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Up 5% for Week
MT Newswires
2 months ago
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading
Insider Monkey
2 months ago
Zai Lab (ZLAB) Delivers Positive ZL-1503 Trial Results in Treatment of Atopic Dermatitis
MT Newswires
2 months ago
Asian Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading
MT Newswires
3 months ago
Zai Lab Reports Positive Results From Preclinical Study of ZL-1503 in Atopic Dermatitis
Business Wire
3 months ago
Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025
Compare ZLAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZLAB Zai Lab Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.